Back to search

Peptide record

TPDB92060

Magainin B Magainin2wisc Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard

23 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92060

Peptide_Name

Magainin B Magainin2wisc

Activity

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb i2APP HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GIGKFLHAAKKFAKAFVAEIMNS-NH2

FASTA

>TPDB92060|Antibacterial;Anticancer;Antifungal;Antiparasitic;Hemolysis;Toxicity|length=23
GIGKFLHAAKKFAKAFVAEIMNS-NH2

Formula C116H184N30O28S1

Absent Amino Acids RDCQPTWY

Common Amino Acids A

Mass 2478.98

PI 10.55

Basic Residues 5

Acidic Residues 1

Hydrophobic Residues 13

Net Charge +3

Boman Index 1.93

Hydrophobicity 0.387

Aliphatic Index 85.22

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

Amino Acid Distribution

A: 5 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 2 H: 1 I: 2 L: 1 K: 4 M: 1 F: 3 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 1

Length

Formula

C116H184N30O28S1

Mass

2478.98

10.55

Net Charge

Boman Index

1.93

Hydrophobicity

0.387

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antibacterial Anticancer

Origin

Xenopus laevis FLAK peptides

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=17 µg/ml

Detail Source Activity Anticancer

Activity Measurement 17 µg/mL

Target

Cancer Type Lymphoma Cancer

Cell Line U-937

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line 8402

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=27 µg/ml

Detail Source Activity Anticancer

Activity Measurement 27 µg/mL

Target

Cancer Type Hematopoietic Cancer

Cell Line SSKT-1

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=28 µg/ml

Detail Source Activity Anticancer

Activity Measurement 28 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line Daudi

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=30 µg/ml

Detail Source Activity Anticancer

Activity Measurement 30 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line MLA

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=23 µg/ml

Detail Source Activity Anticancer

Activity Measurement 23 µg/mL

Target

Cancer Type Lymphoma Cancer

Cell Line Raji

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=32 µg/ml

Detail Source Activity Anticancer

Activity Measurement 32 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=32 µg/ml

Detail Source Activity Anticancer

Activity Measurement 32 µg/mL

Target

Cancer Type Ewing sarcoma

Cell Line CHP-100

Tissue Affected Blood

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=37 µg/ml

Detail Source Activity Anticancer

Activity Measurement 37 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=41 µg/ml

Detail Source Activity Anticancer

Activity Measurement 41 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay Trypan blue assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1990

Evidence 11 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =22 µg/ml

Detail Source Activity Anticancer

Activity Measurement 22 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 12 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =60 µg/ml

Detail Source Activity Anticancer

Activity Measurement 60 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 13 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =130 µg/ml

Detail Source Activity Anticancer

Activity Measurement 130 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 14 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =60 µg/ml

Detail Source Activity Anticancer

Activity Measurement 60 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 15 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =45 µg/ml

Detail Source Activity Anticancer

Activity Measurement 45 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 16 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =125 µg/ml

Detail Source Activity Anticancer

Activity Measurement 125 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2